Showing 5311-5320 of 5771 results for "".
- Bausch + Lomb Introduces Zen Multifocal Scleral Lens for Presbyopiahttps://modernod.com/news/bausch-lomb-introduces-zen-multifocal-scleral-lens-for-presbyopia/2476173/Bausch + Lomb announced the introduction of the Zen multifocal scleral lens for presbyopia, which will be exclusively available with Zenlens and Zen RC scleral lenses through the company’s specialty vision products unit. This innovation will allow eye care professionals to fit presbyopic patients
- Johnson & Johnson Reports 2018 Fourth-Quarter Resultshttps://modernod.com/news/johnson-johnson-reports-2018-fourth-quarter-results/2476175/Johnson & Johnson announced sales of $20.4 billion for the fourth quarter of 2018, an increase of 1.0% as compared with the fourth quarter of 2017. Operational sales results increased 3.3%, and the negative impact of currency was 2.3%. Domestic sales increased 1.
- DORC Unveils Enhancements to the EVA Phacovitrectomy Systemhttps://modernod.com/news/dorc-unveils-enhancements-to-the-eva-phacovitrectomy-system/2476178/DORC has announced the launch several enhancements to its EVA surgical system aimed at delivering both operating room efficiency and surgical performance. The enhancements include a new EVA footswitch that been completely redesigned. Control of the EVA endolaser is now integrated into the
- Aerpio Pharmaceuticals Completes Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-completes-patient-dosing-in-time-2b-study-of-akb-9778-in-diabetic-retinopathy/2476181/Aerpio Pharmaceuticals announced the completion of patient dosing in the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe nonproliferative diabetic retinopathy (NPDR). &#
- Richard Litwin, MD, Honored with ASCRS Foundation’s 2019 Chang Humanitarian Awardhttps://modernod.com/news/richard-litwin-md-honored-with-ascrs-foundations-2019-chang-humanitarian-award/2476188/The Seva Foundation announced that longtime volunteer Richard Litwin, MD, is the 2019 American Society of Cataract & Refractive Surgery (ASCRS) Foundation Chang Humanitarian Award winner. This annual award, which is endowed by Dr. David F. Chang and his wife, Victoria, was created to c
- Survey: 80% of Consumers Would Be More Likely To Visit a Doctor if They Could See the Exact Out-of-Pocket Cost On Their Smartphonehttps://modernod.com/news/survey-80-of-consumers-would-be-more-likely-to-visit-a-doctor-if-they-could-see-the-exact-out-of-pocket-cost-on-their-smartphone/2476190/Metova, a provider of mobile, connected car, connected home and IoT Solutions, announced findings from a “Mobile First” survey on health care and technology, revealing the sentiment of over 1,000 consumers who currently have health care. The survey was conducted to research the growin
- US House Oversight Committee Launches Investigation into Prescription Drug Pricinghttps://modernod.com/news/us-house-oversight-committee-launches-investigation-into-prescription-drug-pricing/2476191/The US House of Representatives’ Oversight Committee on Monday announced a probe into a dozen pharmaceutical companies regarding drug pricing. In the investigation, Representative and committee chairman Elijah Cummings sent letters to AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson
- Atlantic Street Capital Forms Advancing Eyecare Holdings With Partnership of Lombart Instrument and Marco Ophthalmichttps://modernod.com/news/atlantic-street-capital-forms-advancing-eyecare-holdings-with-partnership-of-lombart-instrument-and-marco-ophthalmic/2476196/Private equity firm Atlantic Street Capital announced that it will form Advancing Eyecare Holdings with the partnership of its portfolio company Lombart Instrument, a distributor of ophthalmic instruments, and Marco Ophthalmic, an instrumentation supplier. Terms of the deal were not disclo
- Ocular Therapeutix Submits Supplemental NDA for Dextenza for the Treatment of Postoperative Inflammationhttps://modernod.com/news/ocular-therapeutix-submits-supplemental-nda-for-dextenza-for-the-treatment-of-postoperative-inflammation/2476198/Ocular Therapeutix announced the submission of a supplemental new drug application (NDA) to the FDA for Dextenza (dexamethasone ophthalmic insert). The sNDA filing seeks to expand the current indication for Dextenza to include the treatment of ocular inflammation following ophthalmic surgery. The
- CVP Partners With Northwest and Central Ohio Ophthalmology Practicehttps://modernod.com/news/cvp-partners-with-northwest-and-central-ohio-ophthalmology-practice/2476202/CEI Vision Partners (CVP) announced that Retina Vitreous Associates (RVA) of Toledo, Ohio is now the newest partner practice to join the CVP platform. RVA is a vitreoretinal surgical practice with nine ophthalmologists who specialize in medical and surgical